Insulin Signaling and Autism by Michael Stern
Insulin signaling and autism
Michael Stern*
Department of Biochemistry and Cell Biology, Rice University, Houston, TX, USA
*Correspondence: stern@rice.edu
Autism and autism spectrum disorders 
(ASDs) are thought to be caused mostly by 
genetic factors with an additional contribu-
tion from unidentified environmental risk 
factors. Identifying these environmental risk 
factors could improve both prevention and 
development of therapeutics, but the nature 
of these factors is not well understood.
Clues to the identification of one envi-
ronmental risk factor come from studies of 
a specific set of genetic diseases in which the 
frequency of autism or ASD is significantly 
increased. These diseases include tuberous 
sclerosis (40–50% of afflicted individuals 
have autism), type 1 Neurofibromatosis (a 
several-fold increase in frequency of autism 
in afflicted individuals), and autism with 
macrocephaly (Mansheim, 1979; Gillberg 
and Forsell, 1984; Goffin et al., 2001). As 
has been noted previously by several others 
(for example, see Kelleher and Bear, 2008), 
the genes affected in these disorders, Tsc1/
Tsc2, Nf1, and PTEN, respectively, each 
encode inhibitors of a specific signaling 
pathway called the PI3K/Tor pathway (Hay 
and Sonenberg, 2004). Nf1 encodes a Ras 
GTPase activator protein, which reduces 
the ability of Ras to activate the lipid kinase 
PI3K (Xu et al., 1990; Rodriguez-Viciana 
et al., 1994). PTEN encodes a lipid phos-
phatase that opposes the effects of PI3K. 
Tsc1/Tsc2 encode pathway inhibitors that 
are negatively regulated by PI3K activity 
(Manning et al., 2002). One effect of PI3K/
Tor activity is increased mRNA transla-
tion, which is mediated by activation of the 
translation initiation activator eIF-4E. This 
observation is of interest because a fourth 
disease gene that increases the frequency of 
autism, Fragile X, encodes a translational 
inhibitor that might oppose the effects of 
eIF-4E (Brown et al., 1982; see Figure 1). 
Thus, mutations in any of these four genes 
both increase mRNA translation and 
increase the incidence of autism.
Other evidence supports the idea that 
hyperactivation of the PI3K/Tor path-
way causes autism and ASD. Recently, 
Neves-Pereira et al. (2009) suggested that 
translocations or point mutations that 
hyperactivate eIF-4E are causal for autism. 
In addition, studies of copy-number vari-
ants associated with autism revealed that 
hyperactivated PI3K variants were found 
in numbers far in excess of those expected 
by chance (Serajee et al., 2003; Cuscó et al., 
2009).
In neurons, the PI3K/Tor signaling path-
way affects a form of synaptic plasticity that 
has been implicated in autism (Bear et al., 
2004). This form of synaptic plasticity is 
called long term depression (LTD) medi-
ated by metabotropic glutamate receptors 
(mGluR), which are G protein coupled 
receptors for which glutamate is ligand. The 
best characterized example of mGluR-LTD 
occurs at the synapse between the Schaffer 
collaterals and CA1 pyramidal cells of the 
hippocampus. At this synapse, mGluR-
LTD induction requires dendritic protein 
synthesis (Huber et al., 2001), activation 
of both PI3K and Tor (Hou and Klann, 
2004), and ultimately internalization of 
AMPA-type glutamate receptors (Snyder 
et al., 2001). In addition, loss of Fmr1, the 
protein affected in Fragile X, increases the 
magnitude of mGluR-LTD (Huber et al., 
2002; Waung and Huber, 2009) suggesting 
that Fmr1 normally functions to inhibit 
LTD by inhibiting translation of specific 
dendritic messages. These observations and 
others have led to the proposal that at least 
some of the deficits in autism might reflect 
increased sensitivity to mGluR-LTD induc-
tion (Bear et al., 2004; Kelleher and Bear, 
2008) as a consequence of hyperactivation 
of the PI3K/Tor pathway.
The PI3K/Tor pathway is the major 
intracellular effector of insulin signals, and 
insulin signaling is predicted to activate the 
PI3K/Tor pathway in a manner similar to 
the genetic changes described above (Scott 
et al., 1998). Insulin can cross the blood–
brain barrier (Schwartz and Porte, 2005) 
and insulin receptors are present and can 
regulate synaptic activity in relevant por-
tions of the brain, including the hippocam-
pus, cerebellum, and prefrontal cortex 
(Zhao et al., 2004, 2006; Dou et al., 2005). 
Furthermore, Huang et al. (2004) reported 
that insulin application evokes a LTD of 
synaptic activity (insulin-LTD) in the hip-
pocampal CA1 region that is very similar 
mechanistically to mGluR-LTD: insulin-
LTD, like mGluR-LTD, requires PI3K and 
Tor activity, dendritic protein synthesis, and 
removal of AMPA receptors from the cell 
surface. Thus, it appears that insulin is capa-
ble of activating the precise cellular pathway 
implicated in autism. For these reasons I 
hypothesize that insulin signaling contrib-
utes to development of autism in genetically 
susceptible individuals by contributing to 
PI3K/Tor pathway activation in neurons.
In further support of this hypothesis, 
Gardener et al. (2009) recently reported 
that in a large meta-analysis of maternal 
factors linked to autism, gestational diabe-
tes was associated with the greatest increase 
(twofold) in incidence of autism. Although 
insulin does not cross the placenta, the ele-
vation of fetal blood glucose levels as a con-
sequence of maternal diabetes is predicted 
to increase fetal insulin secretion, and thus 
hyperactivate the fetal PI3K/Tor pathway. 
Another strong risk factor was advanced 
parental age, which may be a consequence 
of an age-dependent impairment of glucose 
tolerance short of diabetes. Furthermore, 
preliminary studies indicated that adminis-
tration of a “ketogenic diet,” in which calo-
ries from carbohydrates are replaced with 
calories from fat, was therapeutic in indi-
viduals with autism and ASD (Evangeliou 
et al., 2003). This effect might result from 
the strong suppression of insulin secretion 
that accompanies this diet (Volek et al., 
2008), which is predicted to attenuate acti-
vation of the PI3K/Tor pathway.
The incidence of gestational diabetes has 
recently increased (Ferrara et al., 2004), an 
increase that might be associated with the 
increased incidence in impaired glucose tol-
erance and hyperinsulinemia in the general 
population. Although the reported inci-
dence of autism and ASD has also increased, 
it is not yet clear if this represents a true 
increase or rather a consequence of greater 
awareness and broader diagnostic criteria. 
However, if a true increase in the incidence 
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of autism is occurring, then this increase 
could be a consequence of the increased 
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eral population.
Thus this hypothesis provides a mecha-
nism for previously unexplained obser-
vations concerning the occurrence and 
treatment of autism as well as for any true 
increase in the incidence of autism and ASD 
that might be occurring. This hypothesis 
also raises new possibilities for prevention 
and therapeutic intervention for autism.
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Figure 1 | Activation of the Pi3K/Tor pathway by insulin and glutamate. The relationships among the 
genes described in the text are shown. Proteins shown in red are PI3K/Tor pathway inhibitors, and autism 
is associated with loss of function mutation in these genes, whereas the proteins shown in green are PI3K/
Tor pathway activators and autism is associated with gain of function alterations in these genes. Proteins 
shown in blue represent other pathway activators. For clarity, several molecular intermediates are omitted. 
See Hay and Sonenberg (2004) for a more complete molecular description of this pathway. 
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